These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 29475590)
1. Validation of Iodine-131-meta-iodobenzylguanidine cardiac scintigraphy in Parkinsonism: A preliminary study. Xu D; Zhu W; Huo L; Zhu S; Li F; Wang H Parkinsonism Relat Disord; 2018 May; 50():69-73. PubMed ID: 29475590 [TBL] [Abstract][Full Text] [Related]
2. MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Chung EJ; Lee WY; Yoon WT; Kim BJ; Lee GH Mov Disord; 2009 Aug; 24(11):1650-5. PubMed ID: 19514077 [TBL] [Abstract][Full Text] [Related]
3. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy]. Yoshita M; Hayashi M; Hirai S Rinsho Shinkeigaku; 1997 Jun; 37(6):476-82. PubMed ID: 9366173 [TBL] [Abstract][Full Text] [Related]
4. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Orimo S; Suzuki M; Inaba A; Mizusawa H Parkinsonism Relat Disord; 2012 Jun; 18(5):494-500. PubMed ID: 22321865 [TBL] [Abstract][Full Text] [Related]
5. Yang T; Wang L; Li Y; Cheng M; Jiao J; Wang Q; Guo H J Neurol Sci; 2017 Feb; 373():48-51. PubMed ID: 28131225 [TBL] [Abstract][Full Text] [Related]
6. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. taki@med.kanazawa-u.ac.jp. Taki J; Nakajima K; Hwang EH; Matsunari I; Komai K; Yoshita M; Sakajiri K; Tonami N Eur J Nucl Med; 2000 May; 27(5):566-73. PubMed ID: 10853813 [TBL] [Abstract][Full Text] [Related]
7. Initial Versus Follow-up Sequential Myocardial 123I-MIBG Scintigraphy to Discriminate Parkinson Disease From Atypical Parkinsonian Syndromes. Ryu DW; Kim JS; Lee JE; Oh YS; Yoo SW; Yoo IR; Lee KS Clin Nucl Med; 2019 Apr; 44(4):282-288. PubMed ID: 30589669 [TBL] [Abstract][Full Text] [Related]
8. The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes. Uyama N; Otsuka H; Shinya T; Otomi Y; Harada M; Sako W; Izumi Y; Kaji R; Watanabe Y; Takashi S; Kunikane Y Nucl Med Commun; 2017 Jun; 38(6):487-492. PubMed ID: 28410288 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes. Fujita H; Suzuki K; Numao A; Watanabe Y; Uchiyama T; Miyamoto T; Miyamoto M; Hirata K PLoS One; 2016; 11(11):e0165869. PubMed ID: 27812167 [TBL] [Abstract][Full Text] [Related]
13. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Treglia G; Cason E; Stefanelli A; Cocciolillo F; Di Giuda D; Fagioli G; Giordano A Clin Auton Res; 2012 Feb; 22(1):43-55. PubMed ID: 21792729 [TBL] [Abstract][Full Text] [Related]
14. [Cardiac sympathetic dysfunction in Parkinson's disease--relationship between results of 123I-MIBG scintigraphy and autonomic nervous function evaluated by the Valsalva maneuver]. Oka H; Yoshioka M; Morita M; Mochio S; Inoue K Rinsho Shinkeigaku; 2003 Aug; 43(8):465-9. PubMed ID: 14658397 [TBL] [Abstract][Full Text] [Related]